🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Wuhan Createrna Science and Technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Wuhan Createrna Science and Technology as lead sponsor. Synced 26 Sep 2026
5Current trials
3Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Wuhan Createrna Science and Technology is the lead sponsor of 5 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are MY008211A, Eculizumab and Sacubitril/valsartan. The most-studied condition is Essential Hypertension.

ClinicalTrials.gov trials by status

  • Recruiting360%
  • Not yet open240%

Trials by phase

  • Phase 3360%
  • Phase 2/3120%
  • Phase 2120%
01

Clinical trials sponsored by Wuhan Createrna Science and Technology

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06933914 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Drug: MY008211A
Phase 2/3 Recruiting 2024-11 China
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
NCT06932744 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Haemoglobinuria (PNH)
Phase 3 Recruiting 2024-08 China
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
NCT06932471 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria
Drug: MY008211A
Phase 3 Recruiting 2024-08 China
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
NCT06716970 · ClinicalTrials.gov ↗ · Essential Hypertension
Phase 3 Not yet open 2024-12 China
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
NCT06687174 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN)
Drug: MY008211A
Phase 2 Not yet open 2024-12 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Wuhan Createrna Science and Technology trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Wuhan Createrna Science and Technology trials

5 conditions
Essential Hypertension1Paroxysmal Nocturnal Hemoglobinuria (PNH)1IgA Nephropathy (IgAN)1Paroxysmal Nocturnal Haemoglobinuria (PNH)1Paroxysmal Nocturnal Hemoglobinuria1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China53

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Essential Hypertension

SponsorTrials
Yi Yang2

Sponsors with the most current trials registered for this condition.

06

Questions about Wuhan Createrna Science and Technology trials

How many clinical trials does Wuhan Createrna Science and Technology sponsor?

Wuhan Createrna Science and Technology is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Wuhan Createrna Science and Technology trials recruiting?

Yes. 3 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Wuhan Createrna Science and Technology testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are MY008211A (4), Eculizumab (1) and Sacubitril/valsartan (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.